Dapagliflozin vs Nivolumab
Dapagliflozin vs Nivolumab: Overview
This comparison examines the pharmacological differences between Dapagliflozin and Nivolumab.
Mechanism of Action
Dapagliflozin: Selective SGLT2 inhibitor reducing renal glucose and sodium reabsorption.
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Dapagliflozin — 12.9 hours; Nivolumab — 27 days.
Chemical Properties
Molecular Formula: Dapagliflozin — C21H25ClO6.
Molecular Weight: Dapagliflozin — 408.8730 g/mol.
Type: Dapagliflozin — Small molecule; Nivolumab — Antibody.